Making Scientists Move Faster

We provide tools and technologies that streamline workflows – from scientific discoveries to new medicines.

About Genovis

The Genovis Group consists of Genovis AB, Sweden, and the wholly owned subsidiary Genovis Inc., USA. The company’s shares are listed on Nasdaq First North Growth Market. Find more information at  Investor Relations.

Genovis offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Genovis enzyme products, SmartEnzymes™, are a unique selection of rapid and easy-to-use enzymatic tools designed to improve the efficacy and throughput in analytical or preparative workflows for complex biopharmaceuticals. The enzymes are used by scientists all over the world, and the innovative product formats facilitate the characterization, development, production, and quality control of biological drugs.

A cornerstone of Genovis’ R&D activities is customer relations that enable product development to meet customer needs. Just as valuable is the collaboration with academic groups that focus on characterizing new enzymes, developing new workflows, and antibodies for novel targets.

Our Core Values

Our core values shape how we work together, how we support our customers, and how we approach new challenges. They reflect what matters to us as a company and help guide the decisions we make every day – from small, everyday choices to long-term direction.

They are not just something we talk about, but something we aim to live by in our daily work contributing to a culture where collaboration, curiosity, and a strong sense of purpose come naturally.

See what guides us

News

Digested Guide to ASMS 2026

2026-05-26

ASMS is always an exciting opportunity to discover new science and innovative mass spectrometry workflows. Throughout the meeting, researchers from around the world will present posters and oral presentations featuring workflows supported by Genovis SmartEnzymes™. In this year’s Digested Guide to ASMS, we’ve gathered selected presentations and posters we’re especially excited to follow. We hope…

More blog posts

Latest Video/Webinar

GlyCLICK® in Action: uPAR-Directed ADC Case Study

2026-05-25

Genoviswebinars - GlyCLICK® in Action: A Versatile Platform for Antibody Conjugation – Preclinical Case Study of uPAR-Directed ADCs

More Videos

“At Genovis, we believe that nature’s innovations can be transformed into technologies that simplify researchers’ work. By developing innovative biological tools and technology platforms, we empower our customers to advance basic research, develop faster and more precise diagnostic tests, and ultimately enable new treatment methods for patients.”